It has been demonstrated that HCC patients presenting with Wnt/β-catenin pathway mutations, including CTNNB1, are less likely to respond to immunotherapy, highlighting the urgency of their early detection [52]. Here, CTNNB1 is linked to hepatocellular carcinoma.